Member Info for Energyshares

This looks like a company that could help Avacta with the Pre/Cision platform in Europe.

MAP Patient Access Ltd.

Market Access For Oncology

MAP has a wide range of experience across a full range of cancer treatments, working in partnership with our clients to accelerate access.

Cancer remains one of the biggest causes of death across Europe. It is one of the largest areas of research for new effective cancer medicines. The range of targeted cancer treatments is growing rapidly which has created new challenges for pricing and reimbursement systems. We can help you navigate these challenges and understand the importance of accelerating access and demonstrating value to payers in a competitive marketplace.

MAP can help you through early engagement, consulting, and our MAP membership to gain successful Market Access for your product.

We can help you

Understand the regulatory and reimbursement challenges faced by oncology medicines and technologies

Develop strong relationships with regulators, payers and KOLs across the sector to help you to engage effectively

Develop your evidence-generation strategy across multiple oncology indications

Develop your strategy all the way from Phase II clinical trials, through evidence generation, regulation and HTA and reimbursement to post-market adoption and implementation

Guess who is Non Executive Chair for MAP Patient Access Ltd.

Avacta’s Non Executive director Shaun Chilton

https://mappatientaccess.com/

Shaun Chilton was most recently Chief Executive Officer ("CEO") of the formerly London-listed Clinigen Group plc ("Clinigen"), a global pharmaceutical and pharmaceutical services platform business,

Shaun has held a number of senior and executive commercial positions over more than 30 years in companies in pharmaceutical and pharmaceutical services industries. These include at Pfizer, Sanofi, Wolters Kluwer Health and KnowledgePoint360 Group (now part of UDG Healthcare).

Another shrewd appointment by the Avacta BOD

Sanofi one of leading BP in Fap.

PL

Is that 1.3 trillion ex (China)

DTW

“ Energy, $665 billion is the conservative estimate. £1.3 trillion is the stretch estimate”

Like Avacta don’t like to be a booster 😂

Today there is $665 billion of comfortable firepower amongst the top 20 companies listed here.

Last page 105

OK who moves first on Avacta.

https://www.stifel.com/Newsletters/InvestmentBanking/BAL/Marketing/Healthcare/Biopharma_TimOpler/Stifel_FirstHalfBiopharmaMarketReview_07.07.2023.pdf

GLA

Fiona,

“ While our lead pre|CISIONTM candidate AVA6000, is progressing through clinical development at pace, we continue to develop other potentially high value assets.”

GLA

“It’s not about the poster, it’s about the timing of presenting it. Why now?”

I agree with BITL

Could it be that one of the leading BP involved with Fap is Sanofi who happens to be the main sponsor of this conference.

https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2/

2 posters will be presented this week,

Affimer today and A3996 on Saturday.

At the last AACR in April

Avacta put out RNS at 7:00am on the morning of poster the 17th April.

Today we have a poster but No RNS

Licence deal attached later perhaps ?

GLA….

Let’s hope Avacta receive FDA feedback like this next year.

Shows how fast FDA can move a drug to market.

https://t.co/TRPPJ7VEPV

Who says MM’s are corrupt how many newbies jumped in this morning and put a stop loss on?

Must of been a few MM’s yes please we will take your shares…

Shocking

O nce

P re/Cision

T rial

I ndicates

O bliteration

N umerous

A vacta

Licensees

I nbound

T hank

Y ou

Bristol Myers Squibb said Sunday it will acquire drugmaker Mirati Therapeutics in a deal worth up to $5.8 billion, adding to its oncology business portfolio.

The company said it will pay $58 per share in cash. As part of the deal, Mirati stockholders will also receive one non-tradeable contingency value for each Mirati share held, potentially worth $12 per share in cash while representing an additional $1 billion of value opportunity, according to the announcement.

https://www.foxbusiness.com/markets/bristol-myers-squibb-buy-cancer-drugmaker-mirati-therapeutics-billion-deal.amp

They still own 50,000 Avacta shares for some reason.

Could a deal be completed this week at the AACR-NCI-EORTC International Conference.

Takeda Ventures, Inc.

Takeda Ventures, Inc. is the corporate venture capital group of Takeda, and was founded in 2001 with the vision of generating disruptive technologies and therapeutic solutions for patients through venture-based investments. Takeda Ventures focuses on high-caliber, therapeutic, platform-based companies around the world.

We specifically invest in early-stage, preclinical opportunities and products which complement Takeda’s pipeline with the mission to create strategic growth opportunities for Takeda through building, managing and investing in innovative companies.

https://www.takeda.com/science/research-and-development/partnerships/cei/

GLA…..

Data rich trial

Watching the results presentation , I noticed on the slide that we all have seen plenty of times the list of cancers and their Fap concentration.

The least on this bar chart was Renal cell cancer and STS was 2nd highest Fap.

So the data rich 1a has data of AVA6000 from the least to the most Fap concentrations of cancers that is on that chart.

GLA

https://www.mskcc.org/cancer-care/clinical-trials/22-428

Truantdox

Just to rub it in.

He can’t say we are getting fast track you don’t push the fda….

Some statement:

"The clinical data emerging for our lead pre|CISIONTM drug, AVA6000, is ground-breaking. We are seeing a dramatic reduction in the usual toxicities associated with anthracycline chemotherapy and we have clear indications that doxorubicin is being released in active form in the tumour microenvironment.

BV

I agree if you remember he was absent from science day and AS gave his apologies

You think a science day planned for months would be a cert he attended.

The last interview on VOX with AS is the last time I can remember him being involved then since then Fiona as stepped in.

Any one who attended AGM did you see him there.

Hope he is ok

Avacta board probably kicking themselves for not taking PI’s extra cash and reducing loan borrowed or even not putting in the cash or shares clause with HCI

The sooner first licence deal arrives and we can pay HCI off the better.

Https://avacta.com/subscription-to-raise-2-million/

Wow

Kamani & Hughes

That’s 13.5 million just on todays SP from £2million outlay.

Imagine £10 T/O which is very conservative that’s

£111 million from £2 million.

Wow again

A positive outcome to this phase I study would require an improved safety profile compared with standard Doxorubicin since the efficacy of this existing chemotherapy is well known.

No wonder Avacta BOD are so positive it’s in the bag….

GLA

Don’t let the MM’s scare you into selling.

How does paradigm shift happen?

A paradigm shift—or paradigm change—happens when scientific activity and experimentation begins to contradict premises that experts previously considered unshakable. As a result, a new and different paradigm replaces the dominant paradigm of its day.